Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

about

A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches

P2860

Q36408534-ABF347D0-488C-4F00-8695-C2442D09F4AD Q58692793-1D19794E-9786-43C2-A057-B9437034F3F5

P2860

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

Item

http://www.wikidata.org/entity/Q35750567

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

@ast

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

@en

type

Item

label

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

@ast

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

@en

prefLabel

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

@ast

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

@en

P1476

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

@en

P2093

Caroline Benedicte Nitter Engen

http://www.w3.org/2001/XMLSchema#string

Jørn Skavland

http://www.w3.org/2001/XMLSchema#string

Line Wergeland

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

P304

1466-1489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JCM3041466

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bjørn Tore Gjertsen

P577

2014-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281846602

http://www.w3.org/2001/XMLSchema#string

P698

26237612

http://www.w3.org/2001/XMLSchema#string

P932

4470194

http://www.w3.org/2001/XMLSchema#string

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

about

P2860

P2860

Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932